Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fluarix Quadrivalent

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

There are no approved vaccines offering simultaneous protection against all five serogroups

- PMLiVE

GSK welcomes Canadian court ruling to dismiss Zantac litigation

The company and other drugmakers have been facing thousands of lawsuits claiming ranitidine caused cancer

- PMLiVE

Novavax announces positive phase 2 results for COVID-19/influenza vaccine candidates

A combination COVID-19/influenza vaccine is included in the mid-stage study

- PMLiVE

GSK’s RSV vaccine approved by FDA for older adults

Arexvy is the first RSV vaccine for this age group to be approved anywhere in the world

- PMLiVE

CureVac announces start of phase 1/2 seasonal influenza vaccine trial

The multivalent mRNA candidates have been developed in collaboration with GSK

- PMLiVE

GSK’s RSV vaccine candidate recommended by CHMP for older adults

RSV infections in older adults account for over 270,000 hospitalisations each year in Europe

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

GSK to acquire Bellus Health for approximately $2bn

The deal includes the biotech’s late-stage candidate for refractory chronic cough

- PMLiVE

GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate

There are currently no licensed vaccines offering simultaneous protection against all five serogroups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links